Horinouchi T, Koike K
Department of Chemical Pharmacology, Toho University School of Pharmaceutical Sciences, Funabashi, Chiba, Japan.
Jpn J Pharmacol. 2000 Nov;84(3):287-92. doi: 10.1254/jjp.84.287.
The properties of the beta1-/beta2-adrenoceptor partial agonist carteolol were investigated in atypical beta-adrenoceptors on the guinea pig gastric fundus. Carteolol induced concentration-dependent relaxation in this tissue (pD2 = 5.55, intrinsic activity = 0.94). However, a combination of the selective beta1-adrenoceptor antagonist atenolol (100 microM) and the selective beta2-adrenoceptor antagonist butoxamine (100 microM) produced only small rightward shifts in the concentration-response curves of carteolol in the gastric fundus (pD2 = 4.91, intrinsic activity = 0.94). In the presence of both atenolol (100 microM) and butoxamine (100 microM), the non-selective beta1-, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol (10-100 microM) caused a concentration-dependent right-ward shift of the concentration-response curves for carteolol in the guinea pig gastric fundus. Schild plot analyses of the effects of (+/-)-bupranolol against carteolol gave the pA2 value of 5.29 and the Schild slope was not significantly different from unity. Furthermore, carteolol (10 microM) weakly but significantly antagonized the relaxant responses to catecholamines ((-)-isoprenaline, (-)-noradrenaline and (-)-adrenaline), a selective beta3-adrenoceptor agonist BRL37344 ((R*,R*)-(+/-)-4-[2-[(2-(3-chlorophenyl)-2-hydroxyethyl)amino]propyl]phenoxy-acetic acid sodium salt) and a non-conventional partial beta3-adrenoceptor agonist (+/-)-CGP12177A ([4-[3-[(1,1dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one] hydrochloride) in the guinea pig gastric fundus. These results suggest that the partial agonistic effects of carteolol are mediated by atypical beta-adrenoceptors in the guinea pig gastric fundus.
在豚鼠胃底的非典型β-肾上腺素能受体上研究了β1-/β2-肾上腺素能受体部分激动剂卡替洛尔的特性。卡替洛尔在该组织中引起浓度依赖性舒张(pD2 = 5.55,内在活性 = 0.94)。然而,选择性β1-肾上腺素能受体拮抗剂阿替洛尔(100μM)和选择性β2-肾上腺素能受体拮抗剂布托沙明(100μM)的组合仅使卡替洛尔在胃底的浓度-反应曲线产生小的右移(pD2 = 4.91,内在活性 = 0.94)。在阿替洛尔(100μM)和布托沙明(100μM)同时存在的情况下,非选择性β1-、β2-和β3-肾上腺素能受体拮抗剂(±)-布普洛尔(10 - 100μM)使豚鼠胃底中卡替洛尔的浓度-反应曲线产生浓度依赖性右移。对(±)-布普洛尔对卡替洛尔作用的Schild图分析得出pA2值为5.29,Schild斜率与1无显著差异。此外,卡替洛尔(10μM)对豚鼠胃底中儿茶酚胺((-)-异丙肾上腺素、(-)-去甲肾上腺素和(-)-肾上腺素)、选择性β3-肾上腺素能受体激动剂BRL37344((R*,R*)-(±)-4-[2-[(2-(3-氯苯基)-2-羟乙基)氨基]丙基]苯氧基乙酸钠盐)和非传统部分β3-肾上腺素能受体激动剂(±)-CGP12177A([4-[3-[(1,1-二甲基乙基)氨基]-2-羟丙氧基]-1,3-二氢-2H-苯并咪唑-2-酮]盐酸盐)的舒张反应有微弱但显著的拮抗作用。这些结果表明,卡替洛尔的部分激动作用是由豚鼠胃底的非典型β-肾上腺素能受体介导的。